This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bernstein, E. D. Articles by Hanna, N. H. Search for Related Content PubMed PubMed Citation Articles by Bernstein, E. D. Articles by Hanna, N. H.

Chemotherapy and Radiotherapy in the Treatment of Resectable Non–Small-Cell Lung Cancer

Department of Medical Oncology, Indiana University, 535 Barnhill Drive, RT 473, Indianapolis, Indiana 46202

Correspondence: Address correspondence and reprint requests to: Nasser H. Hanna, MD; E-mail: nhanna{at}iupui.edu.

Background: Surgical resection remains the cornerstone of therapy for early-stage disease and offers the best chance for cure. Local and distant failure rates, however, remain unacceptably high with surgery alone. Radiation and systemic chemotherapy have been used to reduce recurrences in early-stage disease. Neoadjuvant and adjuvant strategies both offer sound theoretical benefit, but evidence supporting this has been lacking. The publication of a meta-analysis in 1995 triggered a reevaluation of adjuvant chemotherapy. Four randomized trials reported in the last 2 years support the use of adjuvant platinum-based chemotherapy.

Methods: This article reviews the history of clinical trials evaluating neoadjuvant and adjuvant therapy in non–small-cell lung cancer.

Results: Adjuvant chemotherapy improves 5-year survival rates by approximately 5%–15% compared with surgery alone.

Conclusions: Surgical resection followed by adjuvant chemotherapy is the standard of care treatment for patients with completely resected stage I, II, and IIIA non–small-cell lung cancer.

Key Words: Lung neoplasms • Adjuvant chemotherapy • Radiotherapy • Non–small-cell lung carcinoma